Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• 374Water Inc (SCWO) Misses Q2 EPS by 15c
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss